Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.62 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21807285 | 0.89 | MAPK1 (0.52) | ESR2NR1H2MAPK1MAPTNAMPT | |
| SCHEMBL27148063 | 0.83 | ESR2 (0.61) | ESR2NR1H2MAPK1MAPTADORA1 | |
| SCHEMBL29369046 | 0.81 | ESR2 (0.70) | ESR2NR1H2MAPK1MAPTNAMPT | |
| SCHEMBL1202402 | 0.81 | ESR2 (0.70) | ESR2NR1H2MAPK1MAPTNAMPT | |
| Ammonia Solution, Strong SCHEMBL30461763 | 0.80 | ESR2 (0.68) | ESR2NR1H2MAPK1MAPTNAMPT | |
| SCHEMBL31359293 | 0.80 | ESR2 (0.72) | ESR2NR1H2MAPK1MAPTADORA1 | |
| SCHEMBL5599903 | 0.80 | ESR2 (0.72) | ESR2NR1H2MAPK1MAPTADORA1 | |
| SCHEMBL31054069 | 0.80 | ESR2 (0.68) | ESR2NR1H2MAPK1MAPTADORA1 | |
| SCHEMBL19005682 | 0.80 | ESR2 (0.53) | ESR2NR1H2MAPK1MAPTADORA1 | |
| SCHEMBL2132733 | 0.80 | ESR2 (0.53) | ESR2NR1H2MAPK1MAPTADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192689-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| CN-114057739-A | Diazepinone derivatives and their use in the treatment of hepatitis b infections | 诺维拉治疗公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-109641896-B | Diazepinone derivatives and their use in the treatment of hepatitis b infections | 诺维拉治疗公司 | 2021-09-21 | — | — | CN | disclosed |
| US-20170320875-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-11-09 | — | — | US | disclosed |
| US-6265418-B1 | ANTICOAGULANTS | UBE INDUSTRIES, LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| EP-1020467-A1 | N-ACYLAMINO ACID AMIDE COMPOUNDS AND INTERMEDIATES FOR PREPARATION THEREOF | UBE INDUSTRIES LIMITED (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192689-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | ESR2 1345/4885NR1H2 278/4885MAPK1 3802/4885 |
| US-20230145336-A1 | BRAF DEGRADERS | BRAF, NRAS, RAF1 | ESR2 2614/4885NR1H2 3374/4885MAPK1 429/4885 |
| US-20170320875-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | ESR2 1345/4885NR1H2 278/4885MAPK1 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.